Medtronic PLC $MDT Shares Sold by Cambiar Investors LLC

Cambiar Investors LLC lessened its position in shares of Medtronic PLC (NYSE:MDT) by 8.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 589,415 shares of the medical technology company’s stock after selling 52,527 shares during the period. Medtronic comprises 2.6% of Cambiar Investors LLC’s holdings, making the stock its 4th largest position. Cambiar Investors LLC’s holdings in Medtronic were worth $56,136,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the last quarter. V Square Quantitative Management LLC grew its position in Medtronic by 5.9% in the second quarter. V Square Quantitative Management LLC now owns 12,591 shares of the medical technology company’s stock valued at $1,098,000 after purchasing an additional 701 shares in the last quarter. HB Wealth Management LLC increased its stake in Medtronic by 5.4% in the 2nd quarter. HB Wealth Management LLC now owns 101,269 shares of the medical technology company’s stock valued at $8,828,000 after buying an additional 5,192 shares during the last quarter. Finally, XML Financial LLC lifted its position in Medtronic by 16.6% during the 2nd quarter. XML Financial LLC now owns 15,081 shares of the medical technology company’s stock worth $1,315,000 after buying an additional 2,146 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

NYSE:MDT opened at $100.71 on Wednesday. The company has a market cap of $129.12 billion, a P/E ratio of 27.15, a P/E/G ratio of 2.65 and a beta of 0.71. The firm’s fifty day moving average price is $99.52 and its two-hundred day moving average price is $95.48. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. Medtronic’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Analysts Set New Price Targets

A number of analysts recently issued reports on MDT shares. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Morgan Stanley upped their price objective on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Daiwa Capital Markets raised their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. Finally, Citigroup lifted their price objective on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Fourteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).